menu
    • menu

    Company profile for Seven and Eight Biopharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Seven and Eight Biopharmaceuticals Inc. is a biopharmaceutical company devoted to the discovery and development of new targeted cancer immunotherapies. We are the leaders in dendritic cell reprogramming therapies, working with TLR7/8 agonists to activate the innate immunity and generate adaptive immune responses. Established in 2012, Seven and Eight Biopharma was founded with exclusive insight from Dr. Yong-Jun Liu. A propr...
    Seven and Eight Biopharmaceuticals Inc. is a biopharmaceutical company devoted to the discovery and development of new targeted cancer immunotherapies. We are the leaders in dendritic cell reprogramming therapies, working with TLR7/8 agonists to activate the innate immunity and generate adaptive immune responses. Established in 2012, Seven and Eight Biopharma was founded with exclusive insight from Dr. Yong-Jun Liu. A proprietary pipeline of novel cancer drug candidates activating TLR7 and TLR8 were produced, along with a proprietary drug conjugation technology platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Seven and Eight BiopharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    343 Thornall Street, Suite 520 Edison, NJ 08837
    Telephone
    Telephone
    +1 (848) 300-0086
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://7and8biopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/seven-and-eight-biopharmaceuticals-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Seven and Eight Bio Announces Agreement with Eikon for TLR7/8 dual agonists
    Seven and Eight Bio Announces Agreement with Eikon for TLR7/8 dual agonists

    01 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230601005219/en

    BUSINESSWIRE
    01 Jun 2023
    Share Share
    Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows
    Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows

    13 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211113005226/en

    BUSINESSWIRE
    13 Nov 2021
    Share Share
    Seven and Eight Biopharma Announces the 1st Patient Treated a Ph2 Clinical Trial
    Seven and Eight Biopharma Announces the 1st Patient Treated a Ph2 Clinical Trial

    07 Sep 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/seven-and-eight-biopharmaceuticals-inc-announces-the-first-patient-treated-in-a-phase-2-clinical-trial-of-the-tlr-7-8-dual-agonist-bdb001-in-anti-pd-1-anti-pd-l1-refractory-solid-tumors/

    BIOSPACE
    07 Sep 2021
    Share Share
    Seven and Eight Bio Doses First Patient in a Clinical Trial of BDB018
    Seven and Eight Bio Doses First Patient in a Clinical Trial of BDB018

    22 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210623005057/en

    BUSINESSWIRE
    22 Jun 2021
    Share Share
    Seven and Eight Biopharma’s BDB001 Interim Ph1 Data Presented at the 2021 ASCO
    Seven and Eight Biopharma’s BDB001 Interim Ph1 Data Presented at the 2021 ASCO

    07 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210607005546/en/Seven-and-Eight-Biopharma%E2%80%99s-BDB001-in-Combination-with-Pembrolizumab-Shows-Favorable-Safety-and-Clinical-Responses-in-Interim-Phase-1-Data-Presented-at-the-2021-ASCO-Annual-Meeting

    BUSINESSWIRE
    07 Jun 2021
    Share Share
    Institut Bergonié and Seven & Eight Biopharmaceuticals Announce First Patient
    Institut Bergonié and Seven & Eight Biopharmaceuticals Announce First Patient

    18 May 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210518005766/en/Institut-Bergoni%C3%A9-and-Seven-and-Eight-Biopharmaceuticals-Inc.-Announce-the-First-Patient-Treated-in-the-AGADIR-Study-of-BDB001-in-Combination-with-Atezolizumab-and-Immunogenic-Radiotherapy-in-Solid-Tumors

    BUSINESSWIRE
    18 May 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search